CAPR LAWSUIT ALERT: The Gross Law Firm Notifies Capricor Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Core Viewpoint - The Gross Law Firm is notifying shareholders of Capricor Therapeutics, Inc. regarding a potential class action lawsuit due to misleading statements related to the company's lead drug candidate, deramiocel, and its FDA approval process [1][3]. Group 1: Allegations and Impact - Shareholders who purchased Capricor shares between October 9, 2024, and July 10, 2025, are encouraged to contact the firm for possible lead plaintiff appointment [1][4]. - The complaint alleges that Capricor provided investors with misleading information about deramiocel's potential FDA approval while concealing adverse facts from its Phase 2 HOPE-2 trial [3]. - Following the announcement of a Complete Response Letter (CRL) from the FDA on July 11, 2025, which denied the Biologics License Application (BLA) due to insufficient evidence of effectiveness, Capricor's stock price fell from $11.40 to $7.64 per share [3]. Group 2: Next Steps for Shareholders - The deadline for shareholders to register for the class action is September 15, 2025, and there is no cost or obligation to participate [4]. - Registered shareholders will receive updates through a portfolio monitoring software regarding the status of the case [4]. Group 3: Firm's Commitment - The Gross Law Firm aims to protect investors' rights and seeks recovery for those who suffered losses due to false or misleading statements by companies [5].